// changes done below on July 01 2024 // till here on July 01 2024

The viral vector, non-viral vector and gene therapy manufacturing market is projected to grow at a CAGR of ~15% till 2035, claims Roots Analysis 

Published: February 2023

Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors; offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors

Roots Analysis has announced the addition of Viral Vector Manufacturing Market report to its list of offerings. 

Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing.  

To order this 685+ pages report, which features 200+ figures and 285+ tables, please visit https://www.rootsanalysis.com/reports/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html

Key Market Insights

More than 140 stakeholders claim to manufacture viral and non-viral vectors
The market is currently dominated by the presence of various mid-sized industry players (50%); of these 57% of players are contract manufacturers, whereas 22% of players are in-house manufacturers.

Over the time, several advancements have been made for the development of vector based technological platforms 
Majority (37%) of the available technologies are currently used in vector manufacturing followed by those available for manufacturing of cell and gene therapies (16%). Further, 53% of the vector-based technologies are dedicated for the development and manufacturing of adenoviral vectors.

More than 295 partnerships were established between different stakeholders during the last decade
Close to 55% partnerships have been reported post 2018, wherein, maximum partnerships were recorded in year 2022 (till May). Further, maximum partnerships were related to manufacturing (23%) followed by licensing agreement (20%) and product development agreement (15%).

Close to 120 expansion activities have been recorded till 2022, growing at a CAGR of 10%
Majority of the expansions in this domain were related to the establishment of new facility (39%) followed by facility expansion (12%). 

The installed vector manufacturing capacity is estimated to be ~186,150 L
Majority (70%) of total installed capacity is currently available for clinical / commercial stage manufacturing of viral vectors. Further, players headquartered in North America (56%) have the highest installed capacity, across the globe.

Till 2035, the annual demand for vectors is expected to grow at an annualized rate of 11%
Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2035, the demand, in terms of number of patients in clinical and commercial stage, demand for vectors, is projected to be ~ 400 thousand patients.

The market is anticipated to grow at a significant rate, during the period 2022-2035 
The majority share of service revenues is anticipated to come from vector manufacturing projects focused on oncological disorders (51%). By 2035, Europe is likely to capture the major share (42%) of the market  followed by North America (30%) and Asia-Pacific (23%). 

You Can Download Free Sample PDF Copy of This Report At:

Key Questions Answered

  • Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of vectors and gene therapies?
  • Which regions are the current manufacturing hubs for vectors and gene therapies?
  • Which type of technologies are presently offered / being developed by the stakeholders engaged in this domain?
  • Which companies are likely to partner with viral and non-viral vector contract manufacturing service providers?
  • Which partnership models are commonly adopted by stakeholders engaged in this industry?
  • What type of expansion initiatives are being undertaken by players in this domain?
  • Which are the emerging viral and non-viral vectors used by players for the manufacturing of genetically modified therapies?
  • What are the opportunities and threats for the stakeholders engaged in this industry?
  • What is the current, global demand for viral and non-viral vector, and gene therapies?
  • How is the current and future market opportunity likely to be distributed across key market segments?

By 2035, the financial opportunity within the viral vector, non-viral vector and gene therapy manufacturing market has been analyzed across the following segments:

  • Scale of Operation
    • Lab 
    • Clinical
    • Commercial
  • Type of Vectors
    • AAV
    • Adenoviral 
    • Lentiviral
    • Retroviral
    • Plasmid DNA
    • Other Vectors
  • Application Area
    • Gene Therapy
    • Cell Therapy
    • Vaccines
  • Therapeutic Area
    • Oncological Disorders
    • Rare Disorders
    • Neurological Disorders
    • Sensory Disorders
    • Metabolic Disorders
    • Musco-skeletal Disorders
    • Blood Disorders
    • Immunological Diseases
    • Others
  • Geographical Regions 
    • North America
    • Europe
    • Asia Pacific 
    • Latin America
    • MENA
    • Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, the anticipated increase in demand for cell and gene therapies, is the most prominent driver of the growth of the vector supply market. The report includes detailed transcripts of discussion held with prominent industry representatives:

  • Chief Operating Officer, mid-sized company, UK
  • Business Developer, mid-sized company, Netherlands
  • Chief Executive Officer and President, mid-sized company, Netherlands
  • Chief Executive Officer and Chief Scientific Officer, small company, Germany
  • Former Executive and Scientific Director, small company, Belgium
  • Co-Founder and President, mid-sized company, France
  • Former Director, Netherlands-based company
  • Director, Massachusetts-based organization
  • Scientific Director, France-based organization
  • Managing Director, small company, Japan
  • Scientific Director, small company, US
  • Senior Manager Business Development, mid-sized company, Germany
  • Project Manager, small company, Germany
  • Business Development Manager, small company, US
  • ATMP Key Account Manager, France-based organization
  • R&D Leader, small company, France
  • Director of Marketing and Technical Support, mid-sized company, France
  • Head of Marketing and Technology Development, mid-sized company, Spain
  • Independent Consultant

The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), information related to its manufacturing facilities, proprietary vector manufacturing technology and an informed future outlook.:

  • Advanced BioScience Laboratories
  • Aldevron
  • Audentes Therapeutics
  • BioNTech Innovative Manufacturing
  • BioReliance
  • Biovian
  • bluebird bio
  • Cell and Gene Therapy Catapult
  • Celonic
  • Centre for Process Innovation
  • Cobra Biologics
  • Emergent BioSolutions
  • FinVector
  • FUJIFILM Diosynth Biotechnologies
  • Kaneka Eurogentec
  • Lonza
  • MeiraGTx
  • MolMed
  • Novasep
  • Orchard Therapeutics
  • Oxford BioMedica
  • Richter-Helm
  • Sanofi
  • Spark Therapeutics
  • Thermo Fisher Scientific
  • uniQure
  • Vibalogics
  • Vigene Biosciences
  • VIVEbiotech
  • Wuxi AppTech

For additional details, please email at sales@rootsanalysis.com

You may also be interested in the following titles:

  1. Gene Therapy Market
  2. Global Therapeutic Vaccines Market

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry